Biolevate Raises €30 Mn Series A to Scale AI Platform for Life Sciences

Biolevate’s platform uses AI to automate scientific and regulatory work. This helps life sciences companies manage complex tasks more efficiently.

The funding round was co-led by RAISE France and Orange Ventures. MSD Global Health Innovation Fund (MGHIF), Station F and existing investor EQT Ventures also participated in the round.

"We started Biolevate with a mission-driven team united by the belief that AI could improve millions of lives if we empowered the right people and solved the right technological challenges. Today, our vision is becoming reality. Customers are increasingly embracing AI automation at scale, grounded in evidence and under rigorous human oversight, "said Joël Belafa, co-founder and CEO of Biolevate.

Biolevate was founded in Paris by former Dataiku engineers and AI researchers. The company focuses on solving workflow and operational challenges in the life sciences industry.

As AI speeds up drug research and development, pharmaceutical companies have to manage more scientific and regulatory processes. Biolevate aims to make these tasks faster and easier to handle.

The company has built an AI platform for businesses that turns scientific and regulatory information into structured workflows. Its AI keeps its results linked to source evidence, helping companies use AI in regulated environments while keeping human oversight.

Biolevate first developed its platform to help speed up regulatory approval processes. It now supports areas including research, clinical trials, drug discovery, drug development, regulatory documents and health technology assessments. The platform can run up to 100,000 AI agents at the same time.

Read Also- Morphotonics Raises €40 Mn+ in Series B to Scale AI Glasses Manufacturing Technology